Trading Nvidia earnings report? These are the entry and exit levels to watch for
Investing.com - Wells Fargo (NYSE:WFC) lowered its price target on BioNTech (NASDAQ:BNTX) to $150.00 from $170.00 on Tuesday, while maintaining an Overweight rating on the stock. According to InvestingPro data, the company maintains a strong financial position with a healthy balance sheet, holding more cash than debt.
The price target reduction reflects model updates incorporating BioNTech’s collaboration with Bristol Myers (NYSE:BMY) Squibb, according to the research firm.
BioNTech reported second-quarter revenues ahead of expectations, benefiting from COVID-related government revenues and a one-time payment from Pfizer (NYSE:PFE). The company’s R&D expenses were lower due to trial reprioritization, and management reaffirmed both topline and R&D guidance for 2025.
Wells Fargo noted several upcoming oncology updates expected this year, including BNT327 dose optimization data that will determine Phase 3 trial starts and the first adjuvant setting readout for the company’s personalized cancer vaccine.
Management anticipates declining COVID vaccination rates but expects to maintain similar market share above 50% and pricing comparable to 2024 levels, while emphasizing the strategic importance of its vaccine business as the company focuses more deeply on oncology. For detailed analysis and additional insights, including 8 more exclusive ProTips, check out the comprehensive research report available on InvestingPro.
In other recent news, BioNTech reported its second-quarter 2025 revenue, which doubled year-over-year to €260.8 million, surpassing analyst estimates of €137.9 million. Despite this impressive revenue growth, the company posted a net loss of €386.6 million, or -€1.60 per share, slightly worse than the expected -€1.41 per share. TD Cowen raised its price target for BioNTech from $110 to $120, citing the strong Comirnaty sales of €153 million, which exceeded both consensus estimates and the firm’s own projections. Clear Street also adjusted its price target for BioNTech, increasing it from $181 to $185, while maintaining a Buy rating. This adjustment followed BioNTech’s reported revenues of €261 million, which outperformed consensus estimates of €151 million. Additionally, a recent deal with Bristol Myers has bolstered BioNTech’s outlook. These developments reflect a period of significant activity for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.